Impact of preventive therapy on the risk of breast cancer among women with benign breast disease

The Breast - Tập 24 - Trang S51-S55 - 2015
Jack Cuzick1, Ivana Sestak1, Mangesh A. Thorat1
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom

Tài liệu tham khảo

Dupont, 1985, Risk factors for breast cancer in women with proliferative breast disease, N Engl J Med, 312, 146, 10.1056/NEJM198501173120303

Chuba, 2005, Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data, J Clin Oncol, 23, 5534, 10.1200/JCO.2005.04.038

Franceschi, 1998, Second cancers following in situ carcinoma of the breast, Int J Cancer, 77, 392, 10.1002/(SICI)1097-0215(19980729)77:3<392::AID-IJC14>3.0.CO;2-A

Haagensen, 1978, Lobular neoplasia (so-called lobular carcinoma in situ) of the breast, Cancer, 42, 737, 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T

Salvadori, 1991, Risk of invasive cancer in women with lobular carcinoma in situ of the breast, Eur J Cancer, 27, 35, 10.1016/0277-5379(91)90055-I

Page, 1991, Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease, Hum Pathol, 22, 1232, 10.1016/0046-8177(91)90105-X

Rosen, 1978, Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years, Am J Surg Pathol, 2, 225, 10.1097/00000478-197809000-00001

Hartmann, 2015, Atypical hyperplasia of the breast–risk assessment and management options, N Engl J Med, 372, 78, 10.1056/NEJMsr1407164

Collins, 2007, Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study, Cancer, 109, 180, 10.1002/cncr.22408

Hartmann, 2014, Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study, Cancer Prev Res, 7, 211, 10.1158/1940-6207.CAPR-13-0222

Hartmann, 2005, Benign breast disease and the risk of breast cancer, N Engl J Med, 353, 229, 10.1056/NEJMoa044383

El-Wakeel, 2003, Systematic review of fibroadenoma as a risk factor for breast cancer, Breast, 12, 302, 10.1016/S0960-9776(03)00123-1

Ciatto, 1997, Risk of breast cancer subsequent to histological or clinical diagnosis of fibroadenoma–retrospective longitudinal study of 3938 cases, Ann Oncol Off J Eur Soc Med Oncol/ESMO, 8, 297, 10.1023/A:1008263522021

Dupont, 1994, Long-term risk of breast cancer in women with fibroadenoma, N Engl J Med, 331, 10, 10.1056/NEJM199407073310103

McDivitt, 1992, Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group, Cancer, 69, 1408, 10.1002/1097-0142(19920315)69:6<1408::AID-CNCR2820690617>3.0.CO;2-C

Haagensen, 1981

Mannello, 2006, Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies, Breast Cancer Res Treat, 97, 115, 10.1007/s10549-005-9110-y

Dixon, 1999, Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group, Lancet, 353, 1742, 10.1016/S0140-6736(98)06408-3

Bundred, 1991, Is there an increased risk of breast cancer in women who have had a breast cyst aspirated?, Br J Cancer, 64, 953, 10.1038/bjc.1991.433

Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371

Cuzick, 2002, First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial, Lancet, 360, 817, 10.1016/S0140-6736(02)09962-2

Cuzick, 2015, Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial, Lancet Oncol, 16, 67, 10.1016/S1470-2045(14)71171-4

Cuzick, 2014, Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial, Lancet, 383, 1041, 10.1016/S0140-6736(13)62292-8

Goss, 2011, Exemestane for breast-cancer prevention in postmenopausal women, N Engl J Med, 364, 2381, 10.1056/NEJMoa1103507

Tavassoli, 2003, Intraductal proliferative lesions, 63

Elston, 2000, Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology, Eur J Cancer, 36, 1769, 10.1016/S0959-8049(00)00181-7

Gomes, 2014, Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast, Diagn Pathol, 9, 121, 10.1186/1746-1596-9-121

Jain, 2011, Atypical ductal hyperplasia: interobserver and intraobserver variability, Mod Pathol, 24, 917, 10.1038/modpathol.2011.66

Schnitt, 1992, Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria, Am J Surg Pathol, 16, 1133, 10.1097/00000478-199212000-00001

Sloane, 1994, Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U. K. National Coordinating Group for Breast Screening Pathology, Eur J Cancer, 30A, 1414, 10.1016/0959-8049(94)00261-3

Costantino, 1999, Validation studies for models projecting the risk of invasive and total breast cancer incidence, J Natl Cancer Inst, 91, 1541, 10.1093/jnci/91.18.1541

Gail, 1989, Projecting individualized probabilities of developing breast cancer for white females who are being examined annually, J Natl Cancer Inst, 81, 1879, 10.1093/jnci/81.24.1879

Tyrer, 2004, A breast cancer prediction model incorporating familial and personal risk factors, Stat Med, 23, 1111, 10.1002/sim.1668

Boughey, 2010, Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia, J Clin Oncol, 28, 3591, 10.1200/JCO.2010.28.0784

Pankratz, 2008, Assessment of the accuracy of the Gail model in women with atypical hyperplasia, J Clin Oncol, 26, 5374, 10.1200/JCO.2007.14.8833

Waters, 2012, Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010, Breast Cancer Res Treat, 134, 875, 10.1007/s10549-012-2089-2

Kaplan, 2005, Factors affecting breast cancer risk reduction practices among California physicians, Prev Med, 41, 7, 10.1016/j.ypmed.2004.09.041

Taylor, 2005, Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump, Ann Fam Med, 3, 242, 10.1370/afm.284

Port, 2001, Patient reluctance toward tamoxifen use for breast cancer primary prevention, Ann Surg Oncol, 8, 580, 10.1007/s10434-001-0580-9

Worsham, 2007, Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population, Breast J, 13, 115, 10.1111/j.1524-4741.2007.00388.x

Collins, 2006, The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study, Cancer, 107, 1240, 10.1002/cncr.22136

Thông tin
Thông tin xuất bản

The Breast

Tập 24

S51-S55

Thông tin tác giả